Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate following Sen. Bernie Sanders' threat to subpoena the company over the pricing of diabetes drug Ozempic and obesity drug Wegovy.
Tags: Novo Nordisk
Wegovy Now Available to 180 Million Obese in China at $194, Also Not Covered by Insurance
Novo Nordisk launches Wegovy in China, offering an effective weight-loss solution for about 180 million obese Chinese population, though not covered by insurance.
Weight Loss Drugs Users 33% Less Likely to Die From Covid-19, Study Reveals
A new study reveals that semaglutide, a key ingredient in Ozempic and Wegovy, reduces the risk of dying from Covid-19 by 33%, [otentially boosting its market value.
Novo Nordisk, Eli Lilly Shares Decrease After Roche Reveals Obesity Drug Trial
Shares of pharmaceutical companies Novo Nordisk and Eli Lilly slid after Roche announced results from a promising early-stage trial for its proposed obesity drug.
Ozempic, Wegovy Users May Face Rare Blindness Risk, Study Suggests Further Investigation Needed
A new study published in JAMA Ophthalmology suggests that taking Ozempic or Wegovy may increase the risk of developing a rare form of blindness.
Latest News
Telehealth startup Ro has launched a free online tracker to help patients and doctors locate in-stock weight-loss drugs like Wegovy amid national shortages, providing real-time availability and the option to report outages to the FDA.
Amgen witnessed an impressive 12% surge in its shares on Friday, marking its most substantial single-day increase in nearly 15 years.
The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust collaborated to solve global health concerns using science and technology.
Novo Nordisk exceeded profit expectations in Q1 2024 with a 28% surge in net profit, driven by Wegovy's success.
A recent study suggests that Novo Nordisk's diabetes drug, Ozempic, priced at nearly $1,000 in the US, could be produced for less than $5 a month.
The successful weight loss trial of the amycretin pill pushed Novo Nordisk past Tesla in market value to $604 billion, increasing investor interest in innovative solutions for major health issues like obesity.
Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.
Novo AS invests in Ophhtotech Corporation for the further development of drug Fovista. In an announcement made today, Ophthotech Corporation said it was able to raise US$175 million in funding to finance the global Phase 3 clinical program of its lead medication Fovista.
1
